Brought to you by:
Innovation: ISET audience hears what’s on the horizon for CLTI patients
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider, MD, professor of vascular and endovascular surgery at the University of California San Francisco, told delegates attending the International Symposium on Endovascular Therapy…
FDA representatives respond to SWEDEPAD interim analysis, highlight need for continued study
Representatives from the Food and Drug Administration (FDA) referenced “important and reassuring” results from the recent interim analysis of the SWEDEPAD clinical trial in which patients with peripheral arterial disease (PAD) received treatment with paclitaxel-coated or uncoated endovascular devices. However, writing in…
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for paclitaxel devices
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease (PAD) received treatment with paclitaxel-coated (drug-coated balloons or drug-eluting stents) or uncoated endovascular devices, “did not show a difference between the groups in…
New analysis finds DCBs lead to greater four-year survival after fempop revascularization
Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation than those who received treatment using an uncoated device, researchers behind a propensity-matched retrospective review at…
TCT 2020 late-breaking trials session features new data on drug-coated devices
Findings from a series of late-breaking trials in the endovascular field were delivered recently at TCT Connect (Oct. 14–18), the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF), held virtually, with the first from Connie N. Hess, MD,…
Vascular surgeons encouraged to consult talking points document on paclitaxel devices
Vascular surgeons are being encouraged to take consideration of a set of talking points about the risks and benefits of paclitaxel-equipped devices—which has been developed by a multispecialty panel of medical societies—in discussions with their patients. The document is the…
IN.PACT Admiral DCB shows ‘significant advantage’ over uncoated devices in fempop artery treatment analysis
The IN.PACT Admiral drug-coated balloon (DCB) demonstrated a significant advantage in overall survival, amputation-free survival and target-lesion revascularization after femoropopliteal artery treatment through four-year follow-up when compared to uncoated balloons, a single-institution, retrospective review that tackled a head-to-head comparison between…
September slate of regional vascular meetings goes digital
This time last year, the ranks of vascular surgery were gearing up to head for points East, West, Midwest and Northeast as the slew of key regional meetings that take place in the early fall entered their viewfield. But like…
High level of heterogeneity found in randomized PAD trial antithrombotic regimens
A recent systematic review showed that randomized trials comparing different types of peripheral endovascular arterial intervention have a high level of heterogeneity in their antithrombotic regimens. It also revealed an increasing trend for use of dual antiplatelet therapy post intervention…
Six-month IN.PACT AV Access results show superiority of DCB angioplasty
Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulas (AVFs). Furthermore, it was found to be non-inferior with…